<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784262</url>
  </required_header>
  <id_info>
    <org_study_id>011015-01</org_study_id>
    <secondary_id>2015-004377-33</secondary_id>
    <nct_id>NCT02784262</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis</brief_title>
  <official_title>Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic rhinosinusitis (CRS) with nasal polyps is a particularly challenging form of chronic&#xD;
      rhinosinusitis in several ways. Patients have significantly more severe symptom burden and&#xD;
      worse quality of life than patients with chronic rhinosinusitis without nasal polyps. Many&#xD;
      patients return to the health care providers with persistent symptoms after repeated medical&#xD;
      and surgical treatment. Patients have usually tried several different types of treatments,&#xD;
      ranging from less invasive procedures to extensive surgical treatment. The surgical treatment&#xD;
      is often repeated several times. The most common surgical treatment is functional endoscopic&#xD;
      sinus surgery, another established procedure is Vidian neurectomy.&#xD;
&#xD;
      The main object of this pilot study is to investigate the safety of onabotulinumtoxin A&#xD;
      towards the sphenopalatine ganglion (SPG) in CRS patients with nasal polyps. Efficacy data&#xD;
      will also be collected to provide indication on whether future placebo-controlled studies&#xD;
      should be performed.&#xD;
&#xD;
      Onabotulinumtoxin A inhibits the secretion of acetylcholine, blocking the parasympathetic&#xD;
      reflex cascade in the SPG. As a result, the investigators expect less mucosal swelling,&#xD;
      secretion and nasal polyps. The duration of such a blockade is believed to last for 3-9&#xD;
      months and will not lead to damage of the nerve.&#xD;
&#xD;
      This study opens up for improved treatment with less complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">September 4, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>from day 1 to 7 post surgery</time_frame>
    <description>Registration of all adverse events sorted by probable relation to botox or surgery. Data collected from symptom diary, in addition to an open question at consultation and put into the Case Report Form (CRF) by physician or nurse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in symptom index on a visual analog scale nasal obstruction/running nose</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in sinonasal quality of life assessed with the sino-nasal outcome test 22 (SNOT-22)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in nose-sinus related quality of life assessed with a visual analog scale (VAS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the geometrics of the nose assessed by acoustic rhinometry</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in air flow in the nose measured by peak nasal inspiratory flow (PNIF)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in polyp mass assessed by magnetic resonance imaging (MRI)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in polyp mass assessed by computer tomography (CT)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in quality of life expressed by Patients' Global Impression of Change (PGIC)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Disease</condition>
  <condition>Nasal Polyposis</condition>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>botox injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative medication: Paracetamol 1,5g oral, diclofenac 50mg (evt ibuprofen 600mg) oral and/or diazepam 5-10 mg oral.&#xD;
Skin and tissue inside the projected injection canal will be infiltrated with 5-10ml Marcain-Adrenalin (5mg/ml + 5microg/ml) for local anaesthesia.&#xD;
Localization will be confirmed with help of navigation before the medication will be given. Intravascular injection will be prevented by control of aspiration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botox injection Multiguide</intervention_name>
    <description>botox injection under CT/MR navigation and with the navigation tool MultiGuide</description>
    <arm_group_label>botox injection</arm_group_label>
    <other_name>Botulinum toxin type A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  chronic rhinosinusitis with nose polyps (CRSwNP) according to European position paper&#xD;
             on rhinosinusitis and nasal polyps (EPOS) criteria&#xD;
&#xD;
          -  no satisfactory effect of medicinal or surgical treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  systemic or local disease or condition that may result in a higher risk for&#xD;
             complications&#xD;
&#xD;
          -  psychiatric disorder that is indicates against the treatment&#xD;
&#xD;
          -  pregnancy, breastfeeding, fertile female not using contraception&#xD;
&#xD;
          -  abuse of drugs, narcotics or alcohol&#xD;
&#xD;
          -  hypersensitivity against marcain, lidocain, xylocain, or adrenalin, and similar drugs&#xD;
&#xD;
          -  anatomical conditions that hinder injection&#xD;
&#xD;
          -  known sensitivity for botulinum toxin type A or for adjuvant substances&#xD;
&#xD;
          -  treatment with drugs that interact with botulinum toxin type A:&#xD;
&#xD;
          -  suspicion of polyps caused by an allergy&#xD;
&#xD;
          -  suspicion of Samters triade&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Jacob Stovner, md prof</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Jamt√∏y KA, Tronvik E, Bratbak DF, Crespi J, Stovner LJ, Aschehoug I, Thorstensen WM. OnabotulinumtoxinA injection towards the SPG for treating symptoms of refractory chronic rhinosinusitis with nasal polyposis: a pilot study. Acta Otolaryngol. 2021 Oct 11:1-7. doi: 10.1080/00016489.2021.1982146. [Epub ahead of print]</citation>
    <PMID>34633904</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Botulinum Toxin Type A</keyword>
  <keyword>Block</keyword>
  <keyword>Sphenopalatine Ganglion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

